Chinese drug developer Biokin postpones Hong Kong listing, citing ‘market conditions’
Chinese drug developer Sichuan Biokin Pharmaceutical has postponed its Hong Kong share listing, which had been scheduled to begin on Monday, as enthusiasm for initial public offerings (IPOs) in the…